FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
The Filtrate:
Joel Topf
Swapnil Hiremath
Priya Yenebere
Nayan Arora
With Special Guest:
Brendon Neuen Super smart guy and clinical trialist
Michelle Rheault Lead author of DUPLEX and friend of the pod
Show Notes
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
NephJC Summary | PubMed | NEJM
KDIGO FSGS Guidelines 2021 (PDF)
Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications, A Scoping Review (JAMA Internal Medicine)
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)
Vlado Perkovic, mentor and sponsor extradenoire (UNSW Sydney)
Shimer Its a floor wax and a desert topping (TikTok)
SONAR: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease: a double-blind, randomised, placebo-controlled trial. (NephJC)
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (Travere press release)
GFR Slope: Chronic vs Total slope: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure (Nature Medicine)
There are dozens of us! Dozens! (Know your Meme)
Brendon’s Neuen’s tweet about total versus chronic slope (X | Twitter)
Julie R. Ingelfinger, deputy editor for the New England Journal of Medicine (Wikipedia)
You know nothing, John Snow (YouTube shorts)
Tubular Secretions
Swapnil Foundation season two on Apple TV Wheel of Time season two Amazon Prime
Brendon Andor
Priya Poverty, by America Mattew Desmond
Nayan The Armor of Light: A Novel by Ken Follett
Michelle Lessons in Chemistry: A Novel by Bonnie Garmus